IDEAYA Biosciences Inc (IDYA) Stock AnalysisIDYAIDEAYA Biosciences Inc

IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, IDEAYA Biosciences Inc is priced at $36.11, which is below the average analyst price target of $54.75, indicating potential upside. However, the RSI is at 32.43, suggesting it is oversold, and the stock has seen a 5-day change of -3.35%. The main risk lies in the recent negative earnings reports, with an EPS of -1.22, which may affect investor sentiment.